Results 111 to 120 of about 9,311 (148)

Switching from Rituximab to Eculizumab in US Patients with Neuromyelitis Optica Spectrum Disorder: Impact on Hospitalizations. [PDF]

Neurol Ther
Lee J, Kielhorn A, Fam S, Riser E, Flanagan EP.   +4 more
europepmc   +1 more source

The varieties of therapeutic experience: navigating treatment options for patients with PNH. [PDF]

Hematology Am Soc Hematol Educ Program
Bienz M, Patriquin CJ.
europepmc   +1 more source

Molecular determinants of STEC-HUS: from complement activation to microvascular thrombosis. [PDF]

Front Immunol
Santarsiero D, Galbusera M, Gastoldi S, Bresin E, Piras R, Alberti M, Vivarelli M, Prandini S, Conti S, Zotta F, Schubart A, Benigni A, Remuzzi G, Noris M, Aiello S.   +14 more
europepmc   +1 more source

Case Report: Cutaneous Mycobacterium chelonae infection in a kidney transplant recipient with long-term immunosuppression and eculizumab therapy. [PDF]

Front Med (Lausanne)
Sukackiene D, Satkauskaite D, Sleivyte U, Vinikovas A, Ulianskaite G, Pamedys J, Raudonis T, Miglinas M.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Eculizumab☆

Reactions Weekly, 2010
In deep review on eculizumab pharmacology and ...
CATALDI, MAURO, A. Cavaccini
openaire   +3 more sources

Eculizumab

Reactions Weekly, 2023
  +8 more sources

Eculizumab

American Journal of Health-System Pharmacy, 2008
The pharmacology, pharmacokinetics, indications, clinical efficacy, adverse effects, drug interactions, and dosage and administration of eculizumab are reviewed.Eculizumab, a recombinant, humanized, monoclonal, immunoglobulin G antibody produced from murine myeloma cells, is the first agent to be approved for labeling by the Food and Drug ...
openaire   +2 more sources